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Assembling and validating data from
multiple sources to study care for Veterans
with bladder cancer
Florian R. Schroeck1,2,3,4* , Brenda Sirovich1,4, John D. Seigne2,3, Douglas J. Robertson1,4 and Philip P. Goodney1,4
Abstract
Background: Despite the high prevalence of bladder cancer, research on optimal bladder cancer care is limited.
One way to advance observational research on care is to use linked data from multiple sources. Such big data
research can provide real-world details of care and outcomes across a large number of patients. We assembled and
validated such data including (1) administrative data from the Department of Veterans Affairs (VA), (2) Medicare
claims, (3) data abstracted by tumor registrars, (4) data abstracted via chart review from the national electronic
health record, and (5) full text pathology reports.
Methods: Based on these combined data, we used administrative data to identify patients with newly diagnosed
bladder cancer who received care in the VA. To validate these data, we first compared the diagnosis date from the
administrative data to that from the tumor registry. Second, we measured accuracy of identifying bladder cancer care
in VA administrative data, using a random chart review (n = 100) as gold standard. Lastly, we compared the proportion
of patients who received bladder cancer care among those who did versus did not have full text bladder pathology
reports available, expecting that those with reports are significantly more likely to receive care in VA.
Results: Out of 26,675 patients, 11,323 (42%) had tumor registry data available. 90% of these patients had a difference
of 90 days or less between the diagnosis dates from administrative and registry data. Among 100 patients selected for
chart review, 59 received bladder cancer care in VA, 58 of which were correctly identified using administrative data
(sensitivity 98%, specificity 90%). Receipt of bladder cancer care was substantially more common among those who did
versus did not have bladder pathology available (96% vs. 43%, p < 0.001).
Conclusion: Merging administrative with electronic health record and pathology data offers new possibilities to
validate the use of administrative data in bladder cancer research.
Keywords: Bladder cancer, Cystoscopy, Electronic health record, Validity
Background
Bladder cancer is the third and fourth most prevalent
non-cutaneous cancer among men and women in the
United States [1]. In spite of this high prevalence, there
is fairly limited research on what entails optimal bladder
cancer care [2], particularly for the majority of patients
who are living with non-muscle invasive bladder cancer
(NMIBC). This may be due to the fact that examining
bladder cancer care using observational data often
represents a “moving target” [3]. Specifically, patients
with bladder cancer tend to have multiple recurrences
and after each recurrence their pathology and conse-
quently their bladder cancer risk-classification can
change [4, 5], impacting further treatment recommenda-
tions and follow-up [3].
One potential way to advance observational research
on care for NMIBC is to use linked data from multiple
sources to gain a more complete picture of the care pa-
tients receive and of the outcomes of that care. Sources
may include administrative data from hospital electronic
health records (EHR), claims data from Medicare, full
text records (e.g. pathology reports) from the EHR, as
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well as data manually abstracted by chart review. Linking
multiple sources into larger, combined datasets – some-
times called big data research [6] – provides the oppor-
tunity to capture procedures performed, details of
pathology at time of diagnosis and at time of recurrence,
and clinical details that can be abstracted from the pa-
tient chart, thus providing a more complete picture of
patient care and outcomes. Moreover – as done here –
these combined datasets allow for the validation of algo-
rithms and results from the administrative data.
Here, we combine multiple data sources from the De-
partment of Veterans Affairs (VA) Corporate Data
Warehouse (CDW) to assemble a data set that can be
used to study care for patients with bladder cancer. We
describe an algorithm to identify patients with newly di-
agnosed bladder cancer who received bladder cancer
care in VA and then examine its convergent, criterion,
and concurrent validity. These validated data will pro-
vide the opportunity for future detailed research examin-
ing utilization and outcomes of surveillance care among
patients with bladder cancer.
Methods
Data sources
We assembled and linked data from five distinct sources
in order to provide a comprehensive picture of bladder
cancer diagnosis, pathology, and care. This included (1)
administrative data from the VA CDW (including both
inpatient and outpatient encounter data), (2) Medicare
claims data for the Veterans in our cohort, (3) data ab-
stracted by tumor registrars at each individual VA facil-
ity which is then deposited into the CDW, (4) full text
pathology reports from the Text Integration Utility files
available in the CDW, and (5) data abstracted via chart
review from the national electronic health record using
the Compensation and Pension Records Interchange
(CAPRI) and Veterans Health Information Systems and
Technology Architecture (VistA) Web tools.
The VA Information Resource Center (VIReC) rou-
tinely obtains Medicare claims data for Veterans and
matches these to VA data using established algorithms,
based on social security number, gender, and date of
birth [7, 8]. Medicare data for members of our cohort
were then provided by VIReC. Medicare claims data,
tumor registry data, and full text pathology data were
linked using the scrambled social security number, a
unique patient identifier created for research purposes
by VIReC. Data abstracted via chart review were linked
using the real social security number. The study was ap-
proved by the Dartmouth Committee for the Protection
of Human Subjects (#28417) and by the Veteran’s Insti-
tutional Review Board of Northern New England
(#897920-1).
Algorithm to identify patients with newly diagnosed
bladder cancer
We developed an algorithm based on administrative data
to identify a cohort of Veterans with newly diagnosed
bladder cancer. For this, we first identified any patient
66 years of age or older with a diagnosis code for blad-
der cancer (ICD9 codes 188.x, 233.7, 236.7, 239.4) within
the VA CDW outpatient and inpatient files between 01/
01/2005 and 12/31/2011. For the outpatient files, we re-
quired at least two diagnosis codes for bladder cancer at
least 30 days apart to help exclude “rule-out” type diag-
noses (e.g. a patient with a lesion seen on CT scan
prompting a diagnosis code for bladder cancer but later
cystoscopy failing to show a tumor within the bladder)
[9]. We defined the first occurrence of a bladder cancer
diagnosis date as the index date. Next, we excluded any
patients with a preexisting diagnosis of bladder cancer
(ICD9 188.x, 233.7, V10.51) within the VA CDW in-
patient or outpatient data, or within the Medicare Pro-
vider Analysis and Review (MEDPAR), Medicare
Outpatient, or Medicare Carrier files during the 365 days
prior to the index date. Medicare data were queried, be-
cause approximately half of VA patients also receive care
through Medicare [8]. This left us with a cohort of pa-
tients who had a diagnosis code for bladder cancer be-
tween 2005 and 2011 and did not have any preexisting
bladder cancer diagnosis codes. However, a 365 day look
back is arbitrary and may be too short for bladder cancer
patients as some of them may only undergo follow-up
once a year. Thus, we performed sensitivity analyses
after excluding patients with a preexisting diagnosis of
bladder cancer in the 730 days prior to the index date
(n = 23,068). Results from these sensitivity analyses were
not materially different in direction or effect size com-
pared with those of our main analyses, so only the latter
are presented.
Assessing the date of diagnosis – Convergent validity
Convergent validity is defined as the degree to which an
operationalization is similar to (converges on) other
operationalizations that it theoretically should be similar
to [10]. In our study, we assessed convergent validity by
comparing the diagnosis date from the claims algorithm
(that is the index date after applying the 365 day look
back as described above) to the diagnosis date from the
tumor registry among the subset of patient who had
tumor registry data available (Table 1). We calculated
the proportion of patients who had the same diagnosis
date in both sources and whose tumor registry date fell
within a +/− 7 day, 30 day, or 90 day window around
the algorithm-derived index date. In addition, we calcu-
lated the proportion of patients who did not have newly
diagnosed bladder cancer, defined as a tumor registry
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diagnosis date more than 90 days prior to the algorithm-
derived date.
Assessing receipt of bladder cancer care in VA – Criterion
validity
Criterion validity is defined as the performance of an
operationalization against some criterion (gold standard)
[10]. In our study, we assessed criterion validity by
evaluating our ability to identify bladder cancer care in
VA based on administrative data against a chart review
of 100 randomly selected cases as the gold standard. We
defined bladder cancer care as cystoscopy without or
with biopsy or transurethral resection. Using established
methods [11], we classified patients as receiving bladder
cancer care in the VA if they had evidence for these pro-
cedures (see Additional file 1) within the VA administra-
tive data between the index date and study end (12/31/
2014). To better understand whether we can correctly
identify bladder cancer care, we measured the accuracy
of the administrative data to differentiate between pa-
tients who did versus those who did not receive bladder
cancer care in VA (Table 1). For this, we randomly sam-
pled 100 patients out of the entire cohort for a chart re-
view. We used the national electronic health record to
review all relevant clinical notes from 1 year prior to the
index date to at least 2 years after the index date. Based
on this review, we determined whether the patient did
or did not receive bladder cancer care in VA. Using the
chart review as the gold standard, we then calculated
sensitivity, specificity, negative predictive value, positive
predictive value, and accuracy of the claims-based algo-
rithm to identify patients who received bladder cancer
care in VA. We calculated confidence intervals (CIs) for
these measures using a binomial distribution. Finally, we
determined the reasons for not identifying bladder can-
cer care within VA administrative data, using Medicare
enrollment and claims data as well as data from the
chart review.
Assessing our ability to distinguish between groups that
are conceptually more or less likely to receive bladder
cancer care in VA – Concurrent validity
Concurrent validity examines the operationalization’s
ability to distinguish between groups that it should the-
oretically be able to distinguish between [10]. In our
case, patients with full text bladder pathology reports
were highly suspected to have received bladder cancer
care in VA. Thus, our a priori expectation was that re-
ceipt of bladder cancer care in VA should be signifi-
cantly more common among patients who have full text
pathology reports than among those who have not
(Table 1). As previously described, we identified full text
pathology reports based on the report title indicating a
pathology report and on presence of at least one of the
three keywords “bladder”, “urethra”, or “ureter” within
the full text [12]. We then used the chi-squared test to
compare the proportion of patients receiving bladder
cancer care among those who did versus who did not
have pathology reports available.
Results
The final cohort consisted of 26,675 patients with newly
diagnosed bladder cancer, after excluding patients with a
pre-existing bladder cancer diagnosis in either VA ad-
ministrative data or Medicare claims during the 365 days
prior to the index date. Approximately two thirds of
these patients (n = 16,846, 63%) received bladder cancer
care in VA (Fig. 1).
Convergent validity and date of diagnosis
First, we evaluated whether we can correctly identify the
diagnosis date from the administrative data. Thus, we
Table 1 For each type of validity, the question, the comparison, and the rationale for evaluation are shown
Question Comparison Rationale
Can we correctly identify the diagnosis date?
(Convergent validity)
Diagnosis dates from claims algorithm vs
those from tumor registry (n = 11,323)
Tumor registry data are deemed most reliable
because registrars abstracted data directly from the
chart. However, registry data are not available for
all patients, necessitating development of a cohort
based on administrative data.
Can we accurately identify bladder cancer care
received within VA?
(Criterion validity)
Bladder cancer care received in VA based
on administrative data vs chart review
(n = 100)
(1) Assure that algorithm does find all patients
who did get bladder cancer care (sensitivity).
(2) Assure that patients who were identified as
receiving bladder cancer care with the algorithm
actually did receive such care (positive predictive
value).
If we apply the algorithm to the entire cohort, can
we distinguish between groups that are
conceptually more or less likely to receive bladder
cancer care in VA?
(Concurrent validity)
Bladder cancer care received in VA among
patients with vs without full text bladder
pathology reports available (n = 26,675)
Patients with full text bladder pathology reports
are highly suspected to have received bladder
cancer care in VA. Thus, the proportion receiving
bladder cancer care in VA should be significantly
higher among patients who have full text bladder
pathology reports than among those who have
not.
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compared the diagnosis date obtained from the adminis-
trative data to the diagnosis date abstracted by the regis-
trars among the subset of 11,323 patients (42%) with
registry data available. About a quarter of patients (27%)
had the same diagnosis date in both datasets. Ninety
percent had their tumor registry diagnosis date fall
within a 90 day window around the date derived from
the administrative data (Fig. 2). Only 2.9% did not have
newly diagnosed bladder cancer, as their tumor registry
date was more than 90 days prior to the date derived
from the administrative data (Fig. 2).
Criterion validity and receipt of bladder cancer care in VA
Next, we assessed whether we can accurately identify pa-
tients who were newly diagnosed with bladder cancer and
who received bladder cancer care in the VA based on ad-
ministrative data. Using the chart review of 100 cases as
the gold standard, we were able to differentiate patients
who did versus who did not receive bladder cancer care in
VA with an accuracy of 95% (95% CI 89% - 98%). All but
one patient who had bladder cancer care based on chart
review were identified by the use of administrative data
(sensitivity 98%, 95% CI 91% - 100%, Table 2). Among the
62 patients who were identified as receiving bladder can-
cer care with administrative data, 58 actually did receive
such care based on chart review (positive predictive value
94%, 95% CI 84% - 98%, Table 2).
Next, we evaluated reasons for not receiving bladder
cancer care in VA. The most common reasons included
receipt of care outside of the VA among patients who
were enrolled in a Medicare HMO, a recent diagnosis of
bladder cancer with the patient opting for palliative care
only, and a remote history of bladder cancer without any
recent recurrences or follow-up care (Additional file 2).
We also evaluated the four patients who had no evi-
dence for bladder cancer care in the chart review, but
who did have administrative data suggesting such care
(Table 2). These patients had unusual specific circum-
stances, including (1) a remote history of bladder cancer
and cystectomy approximately 40 years ago with need
for recurrent cystoscopic ureteral stent replacements, (2)
Fig. 1 Development of a cohort of patients with newly diagnosed
bladder cancer between 2005 and 2011 who received bladder
cancer care in VA
Fig. 2 Establishing convergent validity by comparing the diagnosis date obtained from the administrative data to the diagnosis date abstracted
by registrars. The histogram shows the percentage of patients that have a given difference between diagnosis dates. The diagnosis date derived
from the administrative data (“algorithm date”) was the same as the tumor registry date among 27% of patients. Just 2.9% of patients did not
have newly diagnosed bladder cancer, because their registry diagnosis date preceded the date obtained from administrative data by more
than 90 days
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a remote history of bladder cancer with subsequent need
for cystoscopy with urethral dilation for a urethral stric-
ture, (3) a patient whose prostate cancer diagnosis was
miscoded as bladder cancer and who underwent a diag-
nostic cystoscopy after his prostate cancer treatment,
and (4) a patient who had a benign ureteral mass excised
and who had a subsequent cystoscopy for stent removal.
Assessing our ability to distinguish between groups that
are conceptually more or less likely to receive bladder
cancer care in VA – Concurrent validity
Finally, we assessed whether we can distinguish between
groups of patients who should be more or less likely to
receive bladder cancer care in VA. Examining the entire
cohort, about two thirds of the cohort (16,846 patients,
63%) had bladder cancer care in VA (Fig. 1). We evalu-
ated whether receipt of bladder cancer care was more
common among those with full text pathology reports in
the database as one would expect. Indeed, the propor-
tion of patients receiving bladder cancer care in VA was
significantly higher among those who had full text path-
ology reports available than among those who had not
(96% vs. 43%, Table 3, p < 0.001).
Discussion
We combined data from multiple sources to validate the
use of administrative data to examine bladder cancer care.
Specifically, we provide evidence that we can accurately
identify patients with newly diagnosed bladder cancer who
received care in the VA healthcare system. Comparison to
tumor registry data showed that we can reliably identify an
approximate diagnosis date for the vast majority of patients.
We also established that we can accurately identify patients
who received bladder cancer care in VA. Lastly, we were
able to validate that patients who were highly likely to have
received bladder cancer care in VA based on the presence
of full text bladder pathology reports overwhelmingly also
had evidence of that care in administrative data.
Our study leverages advantages conferred by add-
itional data sources including full text pathology reports
and chart review of the electronic health record. We
were able to identify patients with newly diagnosed blad-
der cancer who received bladder cancer care in VA with
a positive predictive value of 94%, very similar to the
93.8% positive predictive value reported by a study com-
paring administrative data from a primary care data base
in the UK to a survey mailed to primary care physicians
as the gold standard [13].
In addition to data obtained by chart review, we also
used tumor registry data to validate the algorithm, similar
to prior studies [14–17]. Comparing the diagnosis date
obtained from the VA administrative data to the tumor
registry diagnosis date, we found that about a quarter had
the same date in both sources and for 90% the registry
date fell within a 90 day window around the date obtained
from the administrative data. These findings are very simi-
lar to those obtained in a prior study evaluating the accur-
acy of algorithms to identify newly diagnosed lung,
colorectal, stomach, and breast cancers based on SEER-
Medicare data (about a quarter had diagnosis dates on the
same day and about 90% within a 60 day window) [17].
Our study has several limitations that warrant discus-
sion. First, our approach and findings may not be
generalizable to other big data sets from outside the VA.
Nevertheless, our study highlights the unique opportun-
ity to use big data on a national scale and may inspire
other groups to use similar approaches in their data sets.
Second, we were not able to examine the sensitivity of
the algorithm to identify patients with bladder cancer.
This would have required a national or regional sample
Table 2 Accuracy of administrative data to identify bladder
cancer care in VA among patients with newly diagnosed
bladder cancer, based on chart review of 100 randomly selected
cases (the gold standard). We were able differentiate between
patients who did versus who did not receive bladder cancer
care in VA with high accuracy (95%), with only 5 cases having
discordant data between chart review and algorithm




Based on administrative data Yes 58 4 62
No 1 37 38
Total 59 41
Table 3 Proportion of patients receiving bladder cancer care in VA based on administrative data, comparing those who did versus
who did not have full text bladder pathology reports available. Applying the algorithm to the entire cohort, the proportion receiving
bladder cancer care in VA is significantly higher among patients who have full text pathology reports in VA than among those who
do not (96% vs 43%, p < 0.001, chi-squared test)





Full text pathology available, Percent (N) Yes 96 (9893) 4 (432) 100 (10,325)
No 43 (6953) 57 (9397) 100 (16,350)
Total, Percent (N) 63 (16,846) 37 (9829) 100 (26,675)
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of patients with a confirmed bladder cancer diagnosis
(regardless of their diagnosis codes) and then application
of our algorithm to that cohort to examine whether
these patients could be correctly identified. We did not
have access to such a cohort, because our institutional
review board approval is allowing us only access to pa-
tients with a bladder cancer diagnosis code. However, a
previous study provided evidence of high sensitivity
when identifying bladder cancer patients based on diag-
nosis codes [13]. Third, we acknowledge that only 42%
of patients had tumor registry data available, which ap-
pears to be a low proportion. This is likely related to the
fact that data is only abstracted among patients who re-
ceive their bladder cancer care within the VA. Among
those who received their care in VA, the proportion with
tumor registry data was substantially higher (9258 of
15,352 patients, 60%). Nevertheless, this relatively low
proportion justifies the use of administrative data to as-
semble a cohort of bladder cancer patients for studies in
which it is important to include the entire universe of
patients receiving bladder cancer care.
In spite of these limitations, our study has important
implications. We highlight the advantages of using big
data, that is data from multiple sources merged into one
comprehensive data set. This allowed us to validate the
use of administrative data as done here and will allows us
to develop a more comprehensive understanding of what
does and does not matter when providing care for patients
with bladder cancer in the future. Previously, the use of
observational data to better understand care for patients
with early stage bladder cancer has been hampered by the
lack of important clinical details in most data sets. Care
for early stage bladder cancer has been described as a
“moving target” [3], because each patient’s risk for recur-
rence and progression can change over time. For example,
patients who are diagnosed with a low-risk early stage
bladder cancer may have a recurrence of a high-risk can-
cer and vice versa [4, 5, 18]. Standard administrative and
tumor registry data do not capture granular data on these
recurrences and thus our ability to understand what en-
tails high-quality care for these patients has remained lim-
ited. Our comprehensive data set includes administrative
data from VA and Medicare, data abstracted by tumor
registrars, and full text pathology reports. We expect that
this data set validated herein will now make it possible to
better understand how bladder cancer care is currently
provided and how intensity of cancer care impacts out-
comes such as tumor progression and recurrence.
Conclusions
We demonstrate how merging administrative data with
data from the electronic health record, data abstracted by
tumor registrars, and pathology data offers new possibilities
to validate the use of administrative data. Our validated
cohort will now allow us to comprehensively evaluate care
and outcomes for patients with bladder cancer.
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